Company intelligence / Profile preview

AcuFocus

Irvine, California, United Statesbusinesswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

AcuFocus developed proprietary small aperture ophthalmic devices for vision correction. Its flagship products include the KAMRA corneal inlay for presbyopia and the IC-8 Apthera intraocular lens (IOL) for cataract patients with presbyopia and astigmatism. The IC-8 Apthera IOL is FDA-approved as of July 2022 and available internationally. The company was acquired by Bausch + Lomb in January 2023.

Therapeutic areas: Ophthalmology
Modalities: Device (corneal inlay, intraocular lens)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

IC-8 Apthera

Commercial

Indications: Cataracts, Presbyopia

Beyond the preview

Go deeper on AcuFocus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AcuFocus.

Explore the full profile